Genetic determinants of high density lipoprotein levels

Current Opinion in Lipidology

Volumn 8, Issue 3, 1997, Pages 189-196

  Funke, Harald ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY DISEASE; GENE CONTROL; GENE LOCUS; GENE MUTATION; GENETIC ANALYSIS; GENETIC HETEROGENEITY; GENETIC LINKAGE; HETEROZYGOTE; HUMAN; INTRON; LIPOPROTEIN BLOOD LEVEL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK; SYMPTOM; TANGIER DISEASE;

ANIMALS; CHOLESTEROL, HDL; CORONARY DISEASE; DISEASE MODELS, ANIMAL; GENETIC DISEASES, INBORN; HUMANS; LECITHIN ACYLTRANSFERASE DEFICIENCY; LINKAGE (GENETICS); LIPOPROTEINS, HDL; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE; RISK FACTORS;

EID: 0030878439     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-199706000-00010     Document Type: Review

References (82)

1. Miller NE, Forde OH, Thelle DS, Mjos OD: The Tromso heart-study. High density lipoprotein and coronary heart-disease: a prospective case-control study. Lancet 1977, 1:965-968.
2. Gordon T, Kannel WB, Castelli WP, Dawber TR: Lipoproteins, cardiovascular disease, and death. The Framingham Study. Arch Intern Med 1981, 141:1128-1131.
3. Assmann G, Schulte H: PROCAM-Trial. Panscientia Verlag, Hedingen, Zürich 1986.
4. Glomset JA: The plasma lecithin : cholesterol acyltransferase reaction. J Lipid Res 1968, 9:155-163.
5. von Eckardstein A: Cholesterol efflux from macrophages and other cells. Curr Opin Lipidol1996, 7:308-319.
6. Ordovas JM, Cassidy DK, Civeira F, Bisgaier CL, Schaefer EJ: Familial apolipoproteins A-I, C-III, and A-IV deficiency and premature atherosclerosis due to deletion of a gene complex on chromosome 11. J Biol Chem 1989, 264:16339-16342.
7. Karathanasis SK, Ferris E, Haddad IA: DNA inversion within the apolipoproteins AI/CII/AIV-encoding gene cluster of certain patients with premature atherosclerosis. Proc Natl Acad Sci U S A 1987, 84: 7198-7202.
8. Ng DS, Leiter LA, Vezina C, Connelly PW, Hegele RA: Apolipoprotein A-I Q[-2]X causing isolated apolipoprotein A-I deficiency in a family with analphalipoproteinemia. J Clin Invest 1994, 93:223-239.
9. Navalesi R, Miccoli R, Odoguardi L, Funke H, von-Eckardstein A, Wiebusch H, Assmann G: Genetically determined absence of HDL-cholesterol and coronary atherosclerosis [letter]. Lancet 1995, 346:708-709.
10. Miccoli R, Navalesi R, Odoguardi L, Wessling J, Funke H, Wiebusch H, von Eckardstein A, Assmann G: Compound heterozygosity for a structural apolipoprotein A-I variant, apo A-I (L141R) (Pisa), and an apolipoprotein A-I null allele in patients with absence of HDL-cholesterol, corneal opacifications, and coronary heart disease. Circulation 1996, 94:1622-1628.
11. Schmitz G, Bruning T, Williamson E, Nowicka G: The role of HDL in reverse cholesterol transport and its disturbances in Tangier disease and HDL deficiency with xanthomas. Eur Heart J 1990, (Suppl):197-211.
12. Lackner KJ, Dieplinger H, Nowicka G, Schmitz G: High density lipoprotein deficiency with xanthomas. A defect in reverse cholesterol transport caused by a point mutation in the apolipoprotein A-I gene. J Clin Invest 1993, 92:2262-2273.
13. Nakata K, Kobayashi K, Yanagi H, Shimakura Y, Tsuchiya S, Arinami T, Hamaguch H: Autosomal dominant hypoalphalipoproteinemia due to a completely defective apolipoprotein A-I gene. Biochem Biophys Res Commun 1993, 196:950-955.
14. Takata K, Saku K, Ohta T, Takata M, Bai H, Jimi S, Liu R, Sato H, Kajiyama G, Arakawa K: A new case of apoA-I deficiency showing codon 8 nonsense mutation of the apoA-I gene without evidence of coronary heart disease. Arterioscler Thromb Vasc Biol 1995, 15:1866-1874.
15. Romling R, von Eckardstein A, Funke H, Motti C, Fragiacomo GC, Noseda G, Assmann G: A nonsense mutation in the apolipoprotein A-I gene is associated with high-density lipoprotein deficiency and periorbital xanthelasma: Arterioscler Thromb. 1994, 14:1915-1922.
16. Matsunaga T, Hiasa Y, Yanagi H, Maeda T, Hattori N, Yamakawa K, Yamanouchi Y, Tanaka I, Obara T, Hamaguchi H: Apolipoprotein A-I deficiency due to a codon 84 nonsense mutation of the apolipoprotein A-I gene. Proc Natl Acad Sci USA 1991, 88:2793-2797.
17. Funke H, von Eckardstein A, Pritchard PH, Karas M, Albers JJ, Assmann G: A frameshift mutation in the human apolipoprotein A-I gene causes high density lipoprotein deficiency, partial lecithin: cholesterol-acyltransferase deficiency, and corneal opacities. J Clin Invest 1991, 87:371-376.
18. Booth DR, Tan SY, Booth SE, Tennent GA, Hutchinson WL, Hsuan JJ, Totty NF, Truong O, Soutar AK, Hawkins PN et al.: Hereditary hepatic and systemic amyloidosis caused by a new deletion/insertion mutation in the apolipoprotein al gene. J Clin Invest 1996, 97:2714-2721.
19. Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguyen O, Hutton T, Vigushin DM, Tennent GA, Hutchinson WL et al.: A new apolipoprotein al variant, trp50arg, causes hereditary amyloidosis. QJM Monthly Journal of the Association of Physicians. 1995, 88:695-702.
20. Soutar AK, Hawkins PN, Vigushin DM, Tennent GA, Booth SE, Hutton T, Nguyen O, Totty NF. Feest TG, Hsuan JJ et al.: Apolipoprotein Al mutation Arg-60 causes autosomal dominant amyloidosis. Proc Natl Acad Sci U S A 1992, 89:7389-93.
21. Nichols WC, Gregg RE, Brewer HB Jr, Benson MD: A mutation in apolipoprotein A-I in the Iowa type of familial amyloidotic polyneuropathy. Genomics 1990, 8:318-323.
22. Miettinen H, Gylling H, Ulmanen I, Miettinen TA, Kontula K: Two different allelic mutations in a Finnish family with lecithin:cholesterol acyltransferase deficiency. Arterioscler Thromb Vasc Biol 1995, 15:460-467.
23. Kuivenhoven JA, Stalenhoef AFH, Hill JS, Demacker PNM, Errami A, Kastelein JJP, Pritchard PH: Two novel molecular defects in the LCAT gene are associated with fish eye disease. Arterioscl Thromb Vasc Biol 1996, 16:294-303.
24. Owen JS, Wiebusch H, Cullen P, Watts GF, Lima VLM, Funke H, Assmann G: Complete deficiency of plasma lecithin cholesterol acyltransferase (LCAT) activity due to a novel homozygous mutation (gly 30 ser) in the LCAT gene. Hum Mutation 1996, 8:79-82.
25. Contacos C, Sullivan DH, Rye KA, Funke H, Assmann G: A new molecular defect in the lecithin cholesterol acyltransferase (LCAT) gene associated with fish eye disease. J Lipid Res 1996, 37:35-44.
26. Kuivenhoven JA, Voorst EJGMVT, Wiebusch H, Marcovina SM, Funke H, Assmann G, Pritchard PH, Kastelein JJP, Hill J, Adler L, Errrami AA: Unique genetic and biochemical presentation of fish eye disease. J CIm Invest 1995, 96:2783-2791.
27. Steyrer E, Haubenwallner S, Horl G, Giessauf W, Kostner GM, Zechner RA: Single G to A nucleotide transition in exon IV of the lecithin : cholesterol acyltransferase (LCAT) gene results in an arg(140) to his substitution and causes LCAT deficiency. Hum Genet 1995, 96:105-109.
28. Miller M, Zeller K, Kwiterovich PC, Albers JJ, Feulner G: Lecithin: cholesterol acyltransferase deficiency: identification of two defective alleles in fibroblast cDNA. J Lipid Res 1995, 36:931-8.
29. Moriyama K, Sasaki J, Arakawa F, Takami N, Maeda E, Matsunaga A, Takada Y, Midorikawa K, Yanase T, Yoshino G, et al.: Two novel point mutations in the lecithin : cholesterol acyltransferase (LCAT) gene resulting in LCAT deficiency: LCAT (G873 deletion) and LCAT (Gly334 → Ser). J Lipid Res 1995, 36:2329-43.
30. Kuivenhoven JA, Weibusch H, Pritchard PH, Funke H, Benne R, Assmann G, Kastelein JJP: An intronic mutation in a lariat branchpoint sequence is a direct cause of an inherited human disorder (fish eye disease). J Clin Invest 1996, 98:358-364. The paper demonstrates that a sequence alteration in a lariat consensus sequence is causative for a splicing error in humans. It is the first time that this has been proven in humans.
31. Funke H, van Eckardstein A, Pritchard PH, Albers JJ, Kastelein JJ, Droste C, Assmann G: A molecular defect causing fish eye disease: an amino acid exchange in lecithin : cholesterol acyltransferase (LCAT) leads to the selective loss of alpha-LCAT activity. Proc Natl Acad Sci U S A 1991, 88:4855-9.
32. Klein HG, Lohse P, Pritchard PH, Bojanovski D, Schmidt H, Brewer HB Jr: Two different allelic mutations in the lecithin : cholesterol acyltransferase gene associated with the fish eye syndrome. Lecithin: cholesterol acyltransferase (Thr123-lle) and lecithin: cholesterol acyltransferase (Thr347-Met). J Clin Invest 1992, 89:499-506.
33. Oram JF, Yokoyama S: Apolipoprotein mediated removal of cellular cholesterol and phospholipids. J Lipid Res 1996, 37:2473-2491.
34. Walter M, Reinecke H, Gerdes U, Nofer Jr, Hobbel G, Seedorf U, Assmann G: Defective regulation of phosphatidylcholine specific phospholipases a and d in a kindred with tangier disease: evidence for the involvement of phosphatidylcholine breakdown in hdl mediated cholesterol efflux mechanisms. J Clin Invest 1996, 98:2315-2323.
35. Czarnecka H, Yokoyama S: Regulation of cellular cholesterol efflux by lecithin cholesterol acyltransferase reaction through nonspecific lipid exchange. J Biol Chem 1996, 271:2023-2038. It is shown that a nonspecific net efflux of cholesterol from erythrocytes to lipoproteins is dependent on the LCAT reaction.
36. Marcil M, Boucher B, Krimbou L, Solyrnoss BC, Davignon J, Frohlich J, Genest J: Several familial HDL deficiency in French Canadian kindreds: clinical, biochemical, and molecular characterization. Arterioscl Thromb Vasc Biol 1995, 15:1015-1024.
37. Brown ML, Inazu A, Hesler CB, Agellon LB, Mann C, Whitlock ME, Marcel YL, Milne RW, Koizumi J, Mabuchi H, Takeda R, Tall AR: Molecular basis of lipid transfer protein deficiency in a family with increased high-density lipoproteins. Nature 1989, 342:448-451.
38. Sakai N, Santamarinafojo S, Yamashita S, Matsuzawa Y, Brewer HB: Exon 10 skipping caused by intron 10 splice donor site mutation in cholesterol ester transfer protein gene results in abnormal downstream splice site selection. J Lipid Res 1996, 37:2065-2073.
39. Arai T, Yamashita S, Sakai N, Hirano Ki, Okada S, Ishigami M, Maruyama T, Yamane M, Kobayashi H, Nozaki S et al.: A novel missense mutation (G181X) in the human cholesterol ester transfer protein gene in Japanese hyperalphalipoproteinemic subjects. J Lipid Res 1996, 37:2145-2154.
40. Zhong SB, Sharp DS, Grove JS, Bruce C, Yano K, Curb JD, Tall AR: Increased coronary heart disease in Japanese American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels. J Clin Invest 1996, 97:2917-2923. Carriers of a specific missense mutation in the CETP gene were shown to be associated with elevated HDL-cholesterol concentrations. Despite this potentially favorable effect on plasma lipids CAD showed a higher prevalence in the mutation carriers than in controls. These data confirm that the relation between HDL-cholesterol levels and CAD incidence is of a complex nature.
41. McPerson R, Grundy SM, Guerra R, Cohen JC: Alleleic variation in the gene encoding the cholesteryl ester transfer nprotein is associated with variation in the plasma concentrations of cholesteryl ester transfer protein. J Lipd Res 1996, 37:1743-1748.
42. Tamminen M, Kakko S, Kesaniemi YA, Savolainen MJ: A polymorphic site in the 3′-untranslated region of the cholesteryl ester transfer protein (CETP) gene is associated with low CETP activity. J Lipid Res 1996, 124:237-247.
43. Kinishita M, Teramoto T, Shimazu N, Kaneko K, Ohta M, Koike T, Hosogaya S, Ozaki Y, Kume S, Yamanaka M: CETP is a determinant of serum LDL cholesterol but not HDL cholesterol in healthy Japanese. Atherosclerosis 1996, 120:75-82.
44. Funke H, Wiebusch H, Fuer L, Muntoni S, Schulte H, Assmann G: Identification of mutations in the cholesterol ester transfer protein in Europeans with elevated high density lipoprotein cholesterol (abstract). Circulation 1994, 90:241.
45. Williamson R, Lee D, Hagaman J, Maeda N: Marked reduction of high density lipoprotein cholesterol in mice genetically modified to lack apolipoprotein A-I. Proc Natl Acad Sci U S A 1992, 89:7134-7138.
46. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM: Inhibition of early atherogenesis in transgenic mice by human apolipoprotein Al. Nature 1991, 353:265-267.
47. Schultz JR, Verstuyft JG, Gong EL, Nichols AV, Rubin EM: Protein composition determines the anti-atherogenic properties of HDL in transgenic mice. Nature 1993, 365:762-764.
48. Paszty C, Maeda N, Verstuytt J, Rubin EM: Apolipoprotein Al transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994, 94:899-903.
49. Duverger N, Tremp G, Caillaud JM, Emmanuel F, Castro G, Fruchart JC, Steinmetz A, Denefle P: Protection against atherogenesis in mice mediated by human apolipoprotein A IV. Science 1996, 273:966-968. See [53••].
50. Duverger N, Kruth H, Viglietta C, Castro G, Tailleux A, Fievet C, Fruchart JC, Houdebine LM, Denefle P: Inhibition of atherosclerosis development in cholesterol fed human apolipoprotein A-I transgenic rabbits. Circulation 1996, 94:713-717. See [53••].
51. Seguretmace S, Lattamahieu M, Castro G, Luc G, Fruchart JC, Rubin E, Denefle P, Duverger N: Potential gene therapy for lecithin: cholesterol acyltransferase (LCAT) deficient and hypoalphalipoproteinemic pateints with adenovirus mediated transfer of human LCAT gene. Circulation 1996, 94:2177-2184. See [53••].
52. Hoeg JM, Santamarinafojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SH, Haudenschild CC, Vaisman BL, Hoyt RF, Demosky SJ, et al.: Overexpression of lecithin, cholesterol acyltransferase in transgenic rabbits prevents diet induced atherosclerosis. Proc Natl Acad Sci USA 1996, 93:11448-11453 See [53••].
53. Hoeg JM, Vaisman BL, Demosky SJ, Meyn SM, Talley GD, Hoyt RF, Feldman SH, Berard AM, Sakai N, Wood D, Brousseau ME, Marcovina S, Brewer HB, Santamarinafojo S: Lecithin cholesterol acyltransferase overexpression generates hyperalphalipoproteinemia and a nonatherogenic lipoprotein pattern in transgenic rabbits. J Biol Chem 1996, 271:4396-4402 This series of papers [49•• 53••] describes the overexpression of human genes in transgenic animals. In the animals these genes induce an increase in HDL and reduce the extent of lesion formation in the arterial wall after feeding the animals a cholesterol-rich high fat diet. These data could mean that the presence of high levels of amphipathic proteins has a beneficial effect on rapidly developing diet induced atherosclerosis.
54. Hayek T, Masuccimagoulas L, Jiang X, Walsh A, Rubin E, Breslow JL, Tall AR: Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesterol ester transfer protein transgene. J Clin Invest 1995, 96:2071-2074. Inhibition of atherosclerotic lesion formation in hypertriglyceridemic (human apoC-III overexpressing) mice is observed as the consequence of CETP Overexpression. In normotriglyceridemic mice this is not observed. These data add to the complexity in the relation between HDL and CAD.
55. Jiang X-C, Francone OL, Bruce C, Milne R, Mar J, Walsh A, Breslow JL, Tall AR: Increased preβ-high density lipoprotein, apolipoprotein Al, and phospholipid in mice expressing the human phospholipid transfer protein and human apolipoprotein Al transgenes. J Clin Invest 1996, 98:2373-2380. Overexpression of human phospholipid transfer protein in human apoA-I transgenic mice increases the formation ot preβ-HDL in a two-step process: an initial phospholipid influx into HDL is followed by a cholesterol influx.
56. Albers JJ, Tu AY, Paigen B, Chen H, Cheung MC, Marcovma SM: Transgenic mice expressing human phospholipid transfer protein have increased HDL non HDL cholesterol ratio. Int J Clin Lab Res 1996, 26:262-267. Data in this paper and in [55•] give the first clues on the overall function of phospholipid transfer protein in vivo.
57. Weng W, Breslow JL: Dramatically decreased high density lipoprotein cholesterol, increased remnant clearance, and insulin hypersensitivity in apolipoprotein AII knockout mice suggest a complex role for apolipoprotein AII in atherosclerosis susceptibility. Proc Natl Acad Sci USA 1996, 93:14788-14794. In contrast to humans, mice without apoA-II develop HDL deficiency. Mice are not men is thus the first thought on this report of the lipoprotein phenotype in apoA-II knockout mice. By demonstrating increased remnant clearance and insulin hypersensitivity in these mice the authors showed a complex role of apoAII in lipoprotein metabolism and atherosclerosis susceptibility and limitations in our current knowledge on the metabolism of apoA-II.
58. Marzalcascacuberta A, Blacovaca F, Ishida BY, Julvegil J, Shen JH, Calvetmarquez S, Gonzaleszsastre F, Chan L: Functional lecithin: cholesterol acyltransferase deficiency in transgenic mice overexpressing human apolipoprotein A II. J Biol Chem 1996, 271:6720-6728.
59. Deeb SS, Cheung MC, Peng RL, Wolf AC, Stern R, Albers JJ, Knopp RH: A mutation in the human apolipoprotein A I gene. Dominant effect on the level and characteristics of plasma high density lipoproteins. J Biol Chem 1991, 266:13654-13660.
60. Srinivasan SR, Ehnholm C, Wattigney WA, Bao WH, Berenson GS: The relation of apolipoprotein E polymorphism to multiple cardiovascular risk in children: the Bogalusa Heart Study. Atherosclerosis 1996, 123:33-42.
61. Reymer PWA, Gagne E, Groenemeyer BE, Kastelein JJP, Hayden MR: A lipoprotein lipase mutation ( Asn291Ser) is associated with reduced HDL cholesterol levels in premature atherosclerosis. Nature Genet 1995, 10:28-34.
62. Funke H, Assmann G: The low down on lipoprotein lipase. Nature Genet 1995, 10:6-7.
63. Hunst SC, Hasstedt SJ, Kuida H, Stults BM, Hopkins PN, Williams RR: Genetic heritability and common environmental components of resting and stressed blood pressures, lipids, and body mass index in Utah pedigrees and twins. Am J Epidemiol 1989, 129:625-638.
64. Assmann G, van Eckardstein A, Funke H: High density lipoproteins, reverse transport of cholesterol, and coronary artery disease. Insights from mutations. Circulation 1993, 87(Suppl III):28-34.
65. Acton S, Rigotti A, Landschulz KT, Xu SZ, Hobbs HH, Krieger M: Identification of scavenger receptor SR-B1 as a high density lipoprotein receptor. Science 1996, 271:518-520. Now there is a morphologic substrate of an HDL receptor. This receptor mediates the selective uptake of cholesterol from HDL and thereby antagonizes the function of LCAT on cholesterol flux to these particles [see 35••]. The overall flux of cholesterol between tissues will thus depend on the cholesterol mass handled by this receptor, its expression sites, and the metabolic fate of the incorporated lipid. Liver expression of this receptor may indicate a role for this protein in reverse cholesterol transport.
66. Wang N, Weng W, Breslow JL, Tall AR: Scavenger receptor BI (SR B1) is up regulated in adrenal gland in apolipoprotein Al and hepatic lipase knockout mice as a response to depletion of cholesterol stores: in vivo evidence that SR B1 is a functional high density lipoprotein receptor under feedback control. J Biol Chem 1996, 271:21001-21004. See [68•].
67. Landschulz KT, Pathak RK, Rigotti A, Krieger M, Hobbs HH: Regulation of scavenger receptor, class B, type I, a high density lipoprotein receptor, in liver and steroidogenic tissues of the rat. J Clin Invest 1996, 98:984-995. These two papers [67•,68•] analysed the regulation of the expression of Scavenger receptor BI (HDL receptor). They find that it is expressed in the liver and in steroidogenic tissues under the control of hormones.
68. Schoonjans K, Peinadoonsurbe J, Lefebvre AM, Heyman RA, Briggs M, Deeb S, Staels B, Auwerx J: PPAR alpha and PPAR gamma activators direct a distinct tissue specific transcritional response via a PPRE in the lipoprotein lipase gene. EMBO J 1996, 15:5336-5348. Genes important in fat cell differentiation and the mediation of insulin resistance have now been shown to directly interact with lipoprotein lipase transcription via PPRE.
69. Kim JB, Spiegelman BM: ADD1/SREBP1 promotes adipocyte differentiation and gene expression linked to fatty acid metabolism. Genes Developm 1996, 10:1096-1107.
70. Hotamisligil GS, Johnson RS, Distel RJ, Ellis R, Papaioannou VE, Spiegelman BM: Uncoupling of obesity from insulin resistance through a targeted mutation in AP2, the adipocyte fatty acid binding protein. Science 1996, 274:1377-1379.
71. Peraldi P, Hotamisligil GS, Buurman WA, White MF, Spiegelman BM: Tumor necrosis factor (TNF) alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase. J Biol Chem 1996, 271:13018-13022.
72. Hamsten A: Molecular genetics as the route to understanding, prevention and treatment. Lancet 1996, 348(Suppl):s17-s19.
73. Bennett ST, Todd JA: Human type I diabetes and the insulin gene: principles of mapping polygenes. Annual Rev Genet 1996, 30:343-370.
74. Matise TC: Genome scanning for complex disease genes using the transmission/disequilibrium test and haplotype based haplotype relative risk. Genet Epidemiol 1995, 12:641-645.
75. Mitchel BD, Kammerer CM, Blangero J, Mahaney MC, Rainwater DL, Dyke B, Hixson JE, Henkel RD, Sharp RM, Comuzzi AG et al.: Genetic and environmental contributions to cardiovasclar risk factors in Mexican Americans: the San Antonio Family Heart Study. Circulation 1996, 94:2159-2170. A dissection of the relative contributions of genes and the environment to established CAD risk factors.
76. Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science 1996, 273:1516-1517. This article is a comprehensive presentation of the advantages of association studies over linkage analysis in the investigation of the genetic components of complex diseases.
77. Funke H, Wiebusch H, Schulte H. Assmann G: Additive cooperative effect of three common missense mutations on serum HDL-cholesterol concentrations [Abstract]. Circulation 1996, 94(Suppl):343.
78. Kardassis D, Laccotripe M, Talianidis I, Zannis V: Transcriptional regulation of the genes involved in lipoprotein transport: the role of proximal promoters and long range regulatory elements and factors in apolipoprotein gene regulation. Hypertension 1996, 27:980-1008.
79. 3).
80. Azrolan N, Odaka H, Breslow JL, Fisher EA: Dietary fat elevates hepatic apo Al production by increasing the fraction of apolipoprotein Al mRNA in the translating pool. J Biol Chem 1995, 270:19833-19838.
81. Bennett MK, Lopez JM, Sanchez HB, Osborne TF: Sterol regulation of fatty acid synthase promoter: coordinate feedback regulation of two major lipid pathways. J Biol Chem 1995, 270:25578-25583.
82. Oliveira HCF, Chouinard RA, Agellon LB, Bruce C, Ma LM, Walsh A, Breslow JL, Tall AR: Human cholesteryl ester transfer protein gene proximal promoter contains dietary cholesterol positive response elements and mediates expression in small intestine and periphery while predominant liver and spleen expression is controlled by 5 distal sequences: cis acting sequences mapped in TN transgenic mice. J Biol Chem 1996, 271:31831-31838. Using different promoter constructs in transgenic mice the authors of this paper have demonstrated the presence of three different elements in the CETP promoter which are responsible for expression in (1) liver and spleen, in (2) small intestine, and in (3) adrenals.